Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study.
Jose Maria HuguetVictor García-LorenzoLidia MartíJose María ParedesJose Joaquin RamírezMiguel PastorLucia RuizAna SanahujaPilar TimonedaLaura SanchísGloria Alemany PérezMarta Maia Boscá-WattsPublished in: Biomedicines (2022)
The CT-P13 SC brings a new anti-TNF era. Achieving much higher drug levels that are constant over time opens new paths to explore the management of patients with IBD: less immunogenicity, better perianal disease control and higher achievement of mucosal healing.